Study Details: The data used by the researchers was sourced from TriNetX, a large database with information on approximately 127 million patients from 15 countries, predominantly the United States
These events were generally mild to moderate in severity and included: Nausea often accompanying changes in bowel habits, particularly after dose escalation Diarrhoea loose or watery stools, sometimes with urgency Vomiting less common but reported, especially at higher doses Constipation occurring in some individuals, reflecting the variable effect on gut motility Abdominal discomfort or bloating a sensation of fullness or cramping Flatulence increased wind, which can accompany altered digestion Gastrointestinal adverse events were the most common reason for discontinuation in the Phase 2 trial, occurring in approximately 510% of participants depending on dose group
Individual results vary based on starting weight, dose maintenance, dietary changes, exercise, and program adherence
If treatment ends, patients should be aware that their previous habits and appetite may return, leading them to regain their lost weight
This consequently leads to efficient metabolic function and hence a better and more stable concentration of blood sugar
What happens, what's safe, and what your doctor won't always tell you
